TMDX Options (TMDX20260417P115) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About TMDX20260417P115

Underlying

Transmedics Group, Inc.

Industry

Healthcare Technology

Introduction

TransMedics Group, Inc., was founded in Massachusetts in October 2018. TransMedics, Inc., an operating company and wholly owned subsidiary of TransMedics Group, was incorporated in Delaware in August 1998. The company is a medical technology company dedicated to providing organ transplant treatment to patients with end-stage organ failure in multiple disease states. The company developed the Organ Care System (" OCS ") to replace the standard of care decades ago. OCS represents a paradigm shift that transplants organ preservation from a static to a dynamic environment, enabling new functions including organ optimization and evaluation. The company's OCS technology replicates many aspects of the natural living and functional environment of human external organs. The company has also developed its National OCS Program (" NOP "), an innovative turnkey solution that provides outsourced organ procurement, OCS perfusion management and transplant logistics services to provide a more efficient OCS donor organ procurement process for transplant programs in the United States. The company's transplant logistics services include air transportation, ground transportation and other coordination activities.